<DOC>
	<DOCNO>NCT00027794</DOCNO>
	<brief_summary>RATIONALE : Radical prostatectomy may effective treatment locally advanced prostate cancer . PURPOSE : Phase II trial study effectiveness radical prostatectomy treat patient locally advanced prostate cancer .</brief_summary>
	<brief_title>Radical Prostatectomy Treating Patients With Locally Advanced Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine success rate radical prostatectomy patient locally advance adenocarcinoma prostate . - Determine serious toxic event rate surgery patient . - Determine pN status patient treat surgery . - Determine percentage patient find organ-confined tumor ( pT2 ) undergoing surgery . - Determine 2-year prostate-specific antigen-free survival rate patient treat surgery . - Determine surgical morbidity rate patient treat surgery . OUTLINE : This multicenter study . Patients undergo limited pelvic lymphadenectomy radical retropubic prostatectomy . Patients find pN-positive disease receive treatment accord investigator 's discretion . Patients pN0 disease follow every 3 month 1 year every 4 month 1 year . PROJECTED ACCRUAL : A total 32-74 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Unilateral cT3a , cN0 , M0 Well moderately differentiate tumor Gleason score great 7 ( 4 plus 3 3 plus 4 ) Total serum prostatespecific antigen great 20 ng/mL ( Hybritech equivalent ) PATIENT CHARACTERISTICS : Age : 70 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 9 g/dL Hepatic : Bilirubin great 1.5 time normal ALT AST less 3 time normal PT PTT normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No preexist uncontrolled cardiac disease , sign cardiac failure , rhythm disturbance require therapy No myocardial infarction within past 6 month Pulmonary : No gross abnormality chest xray Other : No disease would preclude surgery No prior malignancy except adequately treat basal cell skin cancer No concurrent primary malignancy No psychological , familial , sociological , geographical condition would preclude compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No prior hormonal therapy would affect assessment clinical T staging , margin positivity , definitive pT stag Radiotherapy : No prior pelvic radiotherapy would affect surgical resectability perioperative morbidity Surgery : No prior surgery small pelvis ( vascular surgery , mesh graft hernia repair , surgery benign prostatic hypertrophy , transurethral resection prostate ) would preclude prostatectomy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>